PaperThe pyrimido-pyrimidine derivatives, dipyridamole, mopidamol (cas 13665-88-8) and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus

Add time:09/06/2019    Source:sciencedirect.com

We compared the effects of dipyridamole, RA-642, and mopidamol (cas 13665-88-8) on platelet activity and thromboxane/prostacyclin balance in relation to the degree of retinal vascularization in a model of experimental streptozotocin-induced diabetes in rats. After 3 months, collagen-induced platelet aggregation in whole blood was 25% higher in diabetic animals than in nondiabetics. Dipyridamole inhibited 43% platelet aggregation, mopidamol 39%, and RA-642 36%. Platelet production of thromboxane B2 was 87% higher in untreated diabetic rats. Mopidamol and RA-642 produced a 46% and 41% inhibition of thromboxane B2. Dipyridamole did not inhibited thromboxane B2 synthesis. Aortic production of 6-keto-PGF1α was 43% lower in untreated diabetic animals and showed no change after treatment with either mopidamol or RA-642. In contrast, dipyridamole caused a 90% increase in aortic production of prostacyclin. Computerized analysis of retinal vascularization showed that untreated diabetic rats had a 81% decrease in the area occupied by peroxidase-labelled vessels as compared with nondiabetics. Treatment with dipyridamole, mopidamol, and RA-642 caused 2.5-fold, 2.8-fold and four-fold increases, respectively, in the percentage of retinal surface occupied by peroxidase-labelled vessels. Differences in retinal vascularization between diabetic animals given RA-642 and nondiabetic controls were negligible.

We also recommend Trading Suppliers and Manufacturers of mopidamol (cas 13665-88-8). Pls Click Website Link as below: cas 13665-88-8 suppliers

Prev:Basic metabolites of pentachloronitrosobenzene (cas 13665-49-1) (PCNO) in livers of female rats
Next:General paperInhibition of ferrous-induced lipid peroxidation by dipyridamole, RA-642 and mopidamol (cas 13665-88-8) in human lung tissue)